Glenmark Pharmaceuticals reported its unaudited financial results for Q3 (Oct-Dec) and nine months ended December 31, 2025. The company experienced revenue growth, but profit was impacted by exceptional costs, including a Rs. 3,232.32 million provision for an antitrust settlement. The financial results reflect both operational successes and the burden of resolving legal challenges.
Financial Overview
Glenmark Pharmaceuticals announced its unaudited financial results for the third quarter (Oct-Dec) and nine months ending December 31, 2025. The consolidated revenue from operations stood at Rs 39,006.15 million for the quarter and Rs 132,119.25 million for the nine-month period. The company’s performance during the quarter was influenced by a mix of revenue growth and exceptional items, impacting profitability.
Impact of Exceptional Items
The company faced significant exceptional costs during the quarter. Specifically, a provision of Rs 3,232.32 million was made for an antitrust and consumer protection settlement in the U.S. This settlement relates to industry-wide allegations concerning price-fixing and market allocation. While the agreement allows the company to resolve the matter, it impacted the bottom line for the financial period.
Segmental Performance and Strategy
The financial performance review occurs at the pharmaceutical business level, which includes both generics and active pharmaceutical ingredient components. Since these elements are interconnected, the company considers its primary reportable segment to be Pharmaceuticals. Efforts are focused on maintaining operational efficiencies and strengthening the product portfolio across various markets.
Settlement Details
Glenmark has agreed to a settlement with the direct purchaser class for US$ 37.75 million. The legal settlement makes clear that Glenmark denies any allegations made against it and the settlement doesn’t mean the company admits liability or any wrongdoing. The company made a provision in its financial statements to cover the approximate settlement amount.
Subsidiaries
The list of subsidiaries as of 31st December 2025, is detailed in Annexure A.
Source: BSE
